Neurocrine Biosciences traded at $105.99 this Friday August 12th, increasing $1.11 or 1.06 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences gained 11.74 percent. Over the last 12 months, its price rose by 18.93 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 101.16 by the end of this quarter and at 92.98 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
105.85
Daily Change
0.92%
Yearly
18.77%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 142.29 0.21 0.15% 22.16%
Acadia Pharmaceuticals 16.23 0.49 3.11% -7.68%
Acorda Therapeutics 0.46 -0.003 -0.74% -87.22%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
ALKERMES 26.13 0.66 2.59% -9.11%
Alnylam Pharmaceuticals 233.39 4.00 1.74% 18.75%
Amgen 248.49 0.14 0.06% 8.19%
Aptinyx Inc 0.41 -0.19 -31.02% -82.83%
Biogen 221.11 2.89 1.32% -35.40%
BioMarin Pharmaceutical 95.02 -0.06 -0.06% 26.64%
Cytokinetics 50.38 0.91 1.84% 56.70%
Dynavax Technologies 16.26 -0.44 -2.61% 23.14%
Enanta Pharmaceuticals 68.06 1.57 2.35% 44.34%
Exelixis 19.50 0.27 1.40% 6.67%
Gilead Sciences 62.87 0.42 0.67% -11.65%
Halozyme Therapeutics 43.51 0.15 0.35% 4.92%
Intercept Pharmaceuticals 17.96 1.89 11.76% 20.38%
Incyte Corp 74.04 0.28 0.38% 0.78%
Ionis Pharmaceuticals 44.27 0.83 1.91% 11.57%
Intra Cellular Therapies 53.77 -3.26 -5.71% 85.21%
Neurocrine Biosciences 105.85 0.97 0.92% 18.77%
Nektar Therapeutics 5.10 0.15 3.03% -64.31%
Pfizer 50.15 1.86 3.85% 3.44%
Prothena 32.26 0.98 3.13% -44.81%
Ultragenyx Pharmaceutical 51.60 0.35 0.68% -44.36%
Regeneron Pharmaceuticals 629.00 5.10 0.82% 0.67%
Repligen 249.18 2.69 1.09% -3.40%
Rigel Pharmaceuticals 1.53 0.13 9.29% -58.87%
Sarepta Therapeutics 109.31 0.05 0.05% 36.74%
Teva Pharmaceutical Industries Ltd 3,644.00 8.00 0.22% 12.43%
Vertex Pharmaceuticals 294.51 2.35 0.80% 51.53%
Xoma 19.59 -0.94 -4.58% -33.64%

Indexes Price Day Year
USND 12975 195.31 1.53% -12.47%
US2000 2008 32.26 1.63% -9.70%

Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.